Search results for "Random"

showing 10 items of 3931 documents

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

A 2 year physical activity and dietary intervention attenuates the increase in insulin resistance in a general population of children: the PANIC stud…

2020

Abstract Aims/hypothesis We studied for the first time the long-term effects of a combined physical activity and dietary intervention on insulin resistance and fasting plasma glucose in a general population of predominantly normal-weight children. Methods We carried out a 2 year non-randomised controlled trial in a population sample of 504 children aged 6–9 years at baseline. The children were allocated to a combined physical activity and dietary intervention group (306 children at baseline, 261 children at 2-year follow-up) or a control group (198 children, 177 children) without blinding. We measured fasting insulin and fasting glucose, calculated HOMA-IR, assessed physical activity and se…

Blood GlucoseMaleEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiologyphysical activitylean body massruokavaliotBody fat percentageHOMA-IRlaw.inventionBody Mass Indexglukoosi0302 clinical medicineRandomized controlled triallawInsulinBody Size030212 general & internal medicineglucoseChildChildreninterventioneducation.field_of_studyBody movementinterventiotutkimusFastingSedentary timebody fatLean body massBody fatBody CompositionFemalefyysinen aktiivisuusinsulinPopulationsedentary time030209 endocrinology & metabolismlapset (ikäryhmät)InterventioninsuliiniArticle03 medical and health sciencesInsulin resistancechildrenHeart rateInternal MedicinemedicineHumanseducationExercisekehonkoostumusbusiness.industryPhysical activityInsulinmedicine.diseaseDietGlucoseLean body massInsulin Resistancebusinessdiet
researchProduct

Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the …

2019

OBJECTIVE: To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. RESEARCH DESIGN AND METHODS: From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical a…

Blood GlucoseMaleResearch designmedicine.medical_specialtyRandomizationEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismSubgroup analysisType 2 diabetesDiet Mediterraneanlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicinePropensity ScoreDiet Fat-RestrictedOlive OilDieta -- Mediterrània Regió de laAgedProportional Hazards ModelsAdvanced and Specialized NursingDiabetisbusiness.industryHazard ratioClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2Multivariate AnalysisPropensity score matchingFemale0405business
researchProduct

Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study.

2019

Key Points Question Is birth weight associated with type 2 diabetes and glycemic traits? Findings This mendelian randomization study found that a 1-SD decrease in birth weight due to the genetic risk score was associated with a higher risk of type 2 diabetes among European and East Asian populations. In addition, a 1-SD decrease in birth weight was associated with a 0.189-SD increase in fasting glucose concentration, but not with fasting insulin, 2-hour glucose, or hemoglobin A1c level. Meaning A genetic predisposition to lower birth weight was associated with an increased risk of type 2 diabetes and increased fasting glucose, suggesting potential mechanisms through which perturbation of th…

Blood GlucoseMaleType 2 diabetes0302 clinical medicineOdds RatioBirth WeightInsulin030212 general & internal medicineOriginal Investigation0303 health sciencesAsia EasternMendelian Randomization AnalysisGeneral MedicineMiddle Aged16. Peace & justice3. Good healthOnline OnlyDiabetes and EndocrinologyFemaletype 2 diabetesAdultmedicine.medical_specialtyDiabetes riskAdolescentBirth weightPolymorphism Single NucleotideWhite People03 medical and health sciencesYoung AdultSDG 3 - Good Health and Well-beingAsian PeopleDiabetes mellitusInternal medicineMendelian randomizationmedicineHumans030304 developmental biologyGlycemicAgedGlycated Hemoglobinbusiness.industryResearchInfant Newbornbirth weightGenetic VariationOdds ratioMendelian Randomization Analysismedicine.diseaseDiabetes Mellitus Type 2mendelian randomization studybusinessJAMA network open
researchProduct

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial

2021

Abstract Background Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage. Aims We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatmen…

Blood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaTime FactorsEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesBlood PressureType 2 diabetesGastroenterologylaw.inventionRandomized controlled triallawPulse wave velocityOriginal InvestigationDiabetesMiddle AgedLipidsVasodilationTreatment OutcomeItalyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyRecombinant Fusion ProteinsIncretinsGlucagon-Like Peptide-1 ReceptorVascular StiffnessDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsDulaglutideAngiologyAgedVascular healthGlycated Hemoglobinbusiness.industrymedicine.diseasedulaglutide diabetes arterial stiffnessImmunoglobulin Fc FragmentsBlood pressureDiabetes Mellitus Type 2lcsh:RC666-701Arterial stiffnessDulaglutidebusinessBiomarkersCardiovascular Diabetology
researchProduct

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.

2021

Digital

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodErectile DysfunctionlawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicineRisk factorAgedbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseasePrognosisImmunoglobulin Fc FragmentsErectile dysfunctionDiabetes Mellitus Type 2Cardiovascular DiseasesDulaglutideFemalebusinessBiomarkersmedicine.drugFollow-Up StudiesThe lancet. Diabetesendocrinology
researchProduct

Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One…

2018

OBJECTIVE The long-term impact of intentional weight loss on cardiovascular events remains unknown. We describe 12-month changes in body weight and cardiovascular risk factors in PREvención con DIeta MEDiterránea (PREDIMED)-Plus, a trial designed to evaluate the long-term effectiveness of an intensive weight loss lifestyle intervention on primary cardiovascular prevention. RESEARCH DESIGN AND METHODS Overweight/obese adults with metabolic syndrome aged 55–75 years (n = 626) were randomized to an intensive weight loss lifestyle intervention based on an energy-restricted Mediterranean diet, physical activity promotion, and behavioral support (IG) or a control group (CG). The primary and seco…

Blood GlucoseMalemedicine.medical_specialtyMediterranean dietEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismOverweightDiet Mediterraneanlaw.inventionPrediabetic State03 medical and health sciences0302 clinical medicineRandomized controlled triallawWeight lossBehavior TherapyRisk FactorsDiabetes mellitusInternal medicineWeight LossInternal MedicineMedicineHumans030212 general & internal medicineObesityExercise physiologyExerciseLife StyleAgedCaloric RestrictionAdvanced and Specialized NursingMetabolic Syndromebusiness.industryLeptinMiddle AgedOverweightmedicine.diseaseExercise TherapyCardiovascular DiseasesFemalemedicine.symptomMetabolic syndromebusinessFollow-Up Studies
researchProduct

Obesity interferes with the orosensory detection of long-chain fatty acids in humans

2014

Background: The association between the orosensory detection of lipids, preference for fatty foods, and body mass index (BMI; in kg/m 2 ) is controversial in humans. Objective: We explored the oral lipid-sensing system and the orosensory-induced autonomic reflex system in lean and obese subjects. Design: Lean (BMI: 19 to ,25; n = 30) and obese (BMI .30; n = 29) age-matched men were enrolled. Their oral threshold sensitivity to linoleic acid (LA) was determined by using a 3-alternative forced-choice ascending procedure, and their eating habits were established by the analysis of 4 consecutive 24-h food-consumption diaries. The effect of brief oral lipid stimulations on plasma triglyceride [(…

Blood GlucoseMaleobesityChemical PhenomenaMESH : Insulin[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionCholesterol VLDLMedicine (miscellaneous)MESH: Food HabitsStimulationMESH: Energy IntakeMESH : TasteMESH : FastingBody Mass Indexchemistry.chemical_compoundMESH: Cholesterol VLDLMESH: Diet RecordsInsulinMESH: ObesityMESH : Physicochemical PhenomenaCompletely randomized designMESH : Food HabitsCross-Over StudiesMESH: Middle AgedMESH : Food PreferencesNutrition and DieteticsFastingMiddle AgedDiet RecordsMESH : TriglyceridesSensory ThresholdsTasteMESH : ObesityMESH: Triglyceridesmedicine.medical_specialtyMESH : MaleLinoleic acidMESH: FastingMESH: InsulinMESH: Cross-Over StudiesMESH: Body Mass IndexLinoleic AcidMESH : Diet RecordsFood PreferencesBMIMESH : Linoleic AcidInternal medicineAutonomic reflexmedicineHumansMESH : Middle AgedhumanMESH: Food PreferencesTriglyceridesMESH : Cholesterol VLDLMESH: Linoleic AcidMESH: HumansCholesterolbusiness.industryMESH : HumansMESH : Energy IntakeFeeding BehaviorMESH : Blood GlucoseMESH : Cross-Over Studiesmedicine.diseaseCrossover studyObesityMESH: Malefat taste[SDV.AEN] Life Sciences [q-bio]/Food and NutritionMESH: Physicochemical PhenomenaMESH : Body Mass IndexEndocrinologychemistryMESH: Blood GlucoseMESH: Tastefood preferenceMESH: Sensory ThresholdsEnergy Intakebusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass indexMESH : Sensory ThresholdsThe American Journal of Clinical Nutrition
researchProduct

Systematic review and assessment of systematic reviews examining the effect of periodontal treatment on glycemic control in patients with diabetes

2017

Objetives There have been several systematic reviews(SRs) on whether periodontal treatment for an individual with both periodontal disease and diabetes can improve diabetes outcomes. The purpose of this investigation was to conduct a systematic review (SR) of previous meta-analyses, and to assess the methodological quality of the SRs examining the effects of periodontal treatment and diabetes. (PROSPERO Registration # CRD 42015023470). Study Design We searched five electronic databases and identified previous meta-analyses of randomized controlled trials published through July 2015. In cases where the meta-analysis did not meet our criteria, the meta-analyses were recalculated. General char…

Blood GlucosePeriodontal treatmentmedicine.medical_specialtyMEDLINElaw.inventionDiabetes Complications03 medical and health sciences0302 clinical medicineMeta-Analysis as TopicRandomized controlled triallawDiabetes mellitusDiabetes MellitusmedicineHumansIn patient030212 general & internal medicineGeneral DentistryPeriodontal DiseasesRandomized Controlled Trials as TopicGlycemicOral Medicine and Pathologybusiness.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseConfidence intervalReview Literature as TopicSystematic reviewOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPhysical therapySurgerybusiness
researchProduct